Regencell Bioscience Holdings (RGC) declined approximately 10.2% over the last 30 days, from $5.88 on July 10 to $5.28 on August 10, 2026. The 30-day slide extends a far steeper quarterly collapse of roughly 81%, with the stock falling from $27.32 in mid-May to current levels near $5.

BIOA closed at $11.72 on Friday, August 7, gaining +3.99% (+$0.45) during regular market hours, extending its post-earnings recovery for a second consecutive session. The move builds on Q2 2026 results reported after the close on August 5, where BIOA beat consensus estimates with EPS of -$0.58 vs. -$0.62 expected and revenue of $2.45M vs. $1.5M consensus.

Hims & Hers Health (HIMS) shares declined approximately 10.9% over the past 30 days, falling from $33.94 on June 26 to $30.24 as of July 27, 2026. The sell-off was primarily triggered by the FDA Pharmacy Compounding Advisory Committee's split decision on July 23–24, which recommended six of seven peptides for compounding but rejected emideltide — one of the most commercially anticipated compounds.

HIMS plunged -13.10% during regular trading on Friday, erasing Thursday's +3.35% FDA-driven gain and hitting intraday lows near $28.41. The primary catalyst was a healthcare sector sell-off triggered by HCA Healthcare's earnings report, which flagged a "negative payer mix shift" from rising uninsured patients that reduced pre-tax income by $400 million.

Amneal Pharmaceuticals (AMRX) surged approximately 24% over the last 30 days, climbing from $13.71 on June 8 to $17.05 by July 7, 2026. The rally was fueled by a series of positive catalysts, including FDA approval of romidepsin injection solution, selection for the FDA PreCheck Pilot Program, and inclusion in multiple Russell 2000 Defensive indexes.

Alkermes shares surged approximately 27.6% over the past 30 days, climbing from $42.76 on June 3 to $54.57 as of July 2, 2026, driven by a series of positive clinical and regulatory catalysts for its lead orexin agonist, alixorexton. The stock has gained roughly 56% over the last quarter, reflecting mounting investor confidence in the company's expanding neuroscience pipeline and sleep-medicine franchise.

Amneal Pharmaceuticals (AMRX) surged approximately 37% over the last 30 days, climbing from around $11.81 on May 19 to $16.21 as of June 18, 2026. The rally was fueled by a strong Q1 2026 earnings beat, the transformative $1.1 billion acquisition of Kashiv BioSciences, and multiple FDA approvals.

Regencell Bioscience Holdings Limited (RGC) shares plunged about 14% in the most recent completed session, dropping to roughly $12.01 from above $14.The sell-off intensified after a wave of law-firm announcements highlighting a pending securities class action and potential DOJ-related investigations into the company’s disclosures and valuation.

TRLV surged approximately 42.6% over the last 30 days, driven by a historic NYSE uplisting and a $50 million share repurchase program. The stock rallied roughly 79% during the most recent quarter, reflecting improving fundamentals and regulatory tailwinds.

Regencell Bioscience Holdings shares tumbled approximately 11.54% in after-hours trading on June 17, 2026, extending a multi-day selloff. The primary catalyst is an intensifying legal storm — multiple securities class action lawsuits and a U.

Zoetis Inc. (ZTS) stock fell approximately 31% over the past 30 days, driven primarily by disappointing first-quarter 2026 earnings results and a lowered full-year guidance.

Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up 4% year-over-year but missing estimates, with a surprise net loss of $92.1 million due to higher costs from shifting to branded GLP-1 (glucagon-like peptide-1) weight-loss drugs. Shares dropped over 14% post-earnings amid margin pressure, though the company raised full-year 2026 revenue guidance to $2.8–$3.0 billion.

Shares of HROW are plunging approximately 21.00% on Tuesday, May 12, 2026, falling from a Monday, May 11 close of $38.04 to approximately $30.05 — a severe earnings-driven selloff following Q1 2026 results released after Monday's close that delivered a deeply missed adjusted EPS of -$0.74 against a -$0.39 consensus estimate (a 90% miss),

HIMS shares are down approximately 15.15% in premarket trading on Tuesday, May 12, 2026, falling from Monday's closing price of $29.14 to around $24.73. The primary catalyst is a significant Q1 2026 earnings miss: the company reported an EPS loss of -$0.40, compared to the analyst consensus estimate of +$0.04 — swinging from a profit of $0.20 per share in Q1 2025.

Takeda to report FY2025 Q4 and full-year results on May 13, 2026, before U. S.

Analysts expect Q4 FY26 revenue of approximately $887 million, a potential decline due to softer U. S.

Analysts expect Q1 2026 revenue of approximately $617 million, up 5% from $586 million in Q1 2025. Consensus EPS estimate stands at $0.03, reflecting a sharp decline from $0.20 in the year-ago quarter amid higher costs.

ZTS shares plunged approximately 13.81% in premarket trading on May 7, 2026, falling from a prior close of $111.22 to around $95.86. The primary catalyst was a disappointing Q1 2026 earnings report released before the market open, with both revenue and adjusted EPS missing Wall Street consensus estimates.

TEVA stock surged approximately +20% over the past 30 days, driven primarily by strong Q1 2026 earnings that beat estimates and robust growth in branded drugs like AUSTEDO. The stock experienced volatility over the past quarter, ending roughly flat with a +strong performance amid broader market pressures and generics challenges, offset by innovative portfolio momentum.

Aurora Cannabis shares have shown volatility in recent weeks, trading near the lower end of their 52-week range amid broader sector pressures. Strategic acquisition of Safari Flower Company bolsters EU Good Manufacturing Practice (GMP) capacity for high-margin international medical sales.